EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Effectiveness and Safety of Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive and Oligometastatic Hepatocellular Carcinoma

Zhuo Song iD, Xuan Zheng iD, Hongzhi Wang, Dezuo Dong, Xianggao Zhu, Jianhao Geng, Shuai Li iD, Maxiaowei Song, Rongxu Du, Yangzi Zhang, Zhiyan Liu, Yong Cai iD und 2 weitere

Journal of Hepatocellular Carcinoma · 2025-05 · Volume 12 · 1097-1110

DOI: 10.2147/jhc.s519770 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2025-05. Verfasst von Zhuo Song und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Canc…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study explored the efficacy and safety of combining systemic therapy with stereotactic body radiotherapy (SBRT) for oligoprogressive (OP) and oligometastatic (OM) hepatocellular carcinoma (HCC). Patients and Methods: From January 2017 to June 2023, 37 HCC patients (28 OP, 9 OM) receiving systemic therapy and SBRT were identified. OP is defined as up to 5 progressive lesions with others stable after systemic therapy and OM as newly identified metastatic disease with up to 5 metastatic lesions. SBRT was delivered in fractions of 5 Gy or more to all lesions. Clinical outcomes and toxicity were evaluated.

Results

The median follow-up was 32.8 months. The objective response rates (ORRs) were 47.2%, 44.4%, and 55.5% for overall, OP, and OM cohorts. SBRT treated 48 OP and 17 OM lesions, achieving an ORR of 64.7%. For overall, OP, and OM cohorts, the 2-year local failure rates were 3.0%, 4.0%, and 0%, with median progression-free survival (PFS) of 11.2, 11.2, and 10.2 months, and median overall survival (OS) of 34.9 months, 32.6 months, and not reached (NR), respectively. In the OP cohort, 12 patients switched to next-line systemic therapy (OP-N) and 16 remained on current therapy (OP-C). Median PFS and OS were 11.6 months and NR for OP-N versus 16.5 months and 32.6 months for OP-C (P=0.89 and 0.47). Grade 3 acute and late treatment-related adverse events occurred in 40.5% and 5.4% of patients.

Conclusion

Systemic therapy combined with SBRT was effective and safe for OP and OM HCC. SBRT may delay next-line systemic therapy by blocking OP. Combining systemic therapy with stereotactic body radiotherapy (SBRT) represents a promising treatment strategy for oligoprogressive (OP) and oligometastatic (OM) hepatocellular carcinoma.This study demonstrates that SBRT combined with systemic therapy may offer favorable short-term response and long-term outcomes while maintaining a good safety profile.OP patients who continue their current systemic therapy while receiving SBRT may block OP status and achieve outcomes comparable to those who switch therapies, highlighting the potential of this approach to delay treatment changes and improve outcomes.

Schlagwörter

Stichwörter der Autor:innen

efficacyhepatocellular carcinomaoligometastaticoligoprogressivesafetystereotactic body radiotherapy

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, People's Republic of China.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Radiation Oncology, Peking University Cancer Hospit…

ORCID-Profile: Zhuo Song, Xuan Zheng, Shuai Li, Yong Cai, Yongheng Li

Zitieren

APA

Song, Z., Zheng, X., Wang, H., Dong, D., Zhu, X., Geng, J., Li, S., Song, M., Du, R., Zhang, Y., Liu, Z., Cai, Y., Li, Y., & Wang, W. (2025). Effectiveness and Safety of Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive and Oligometastatic Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, Volume 12, 1097-1110. https://doi.org/10.2147/jhc.s519770

Vancouver

Song Z, Zheng X, Wang H, Dong D, Zhu X, Geng J, et al. Effectiveness and Safety of Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive and Oligometastatic Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2025;Volume 12:1097-1110. doi:10.2147/jhc.s519770

BibTeX
@article{Song2025,
  author = {Song, Zhuo and Zheng, Xuan and Wang, Hongzhi and Dong, Dezuo and Zhu, Xianggao and Geng, Jianhao and Li, Shuai and Song, Maxiaowei and Du, Rongxu and Zhang, Yangzi and Liu, Zhiyan and Cai, Yong and Li, Yongheng and Wang, Weihu},
  title = {Effectiveness and Safety of Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive and Oligometastatic Hepatocellular Carcinoma},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2025},
  volume = {Volume 12},
  pages = {1097--1110},
  doi = {10.2147/jhc.s519770}
}
Kostenlos starten →